Eton Pharmaceuticals, Inc. Proceeds from Issuance or Sale of Equity
Eton Pharmaceuticals, Inc. (ETON) reported Proceeds from Issuance or Sale of Equity of $453.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-05.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2020-03-05
- Eton Pharmaceuticals, Inc. proceeds from issuance or sale of equity for the quarter ending 2019-12-31 was $171.00K.
- Eton Pharmaceuticals, Inc. proceeds from issuance or sale of equity for the quarter ending 2019-09-30 was $77.00K.
- Eton Pharmaceuticals, Inc. proceeds from issuance or sale of equity for fiscal 2019 was $453.00K.
| Period end | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 6 month | Proceeds from Issuance or Sale of Equity 9 month | Proceeds from Issuance or Sale of Equity 12 month |
|---|---|---|---|---|
| 2019-12-31 | $171.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $248.00K derived: sum of 2 quarters · filed 2020-03-05 | $453.00K 10-K · filed 2020-03-05 | |
| 2019-09-30 | $77.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $282.00K 10-Q · filed 2019-11-14 | ||
| 2019-06-30 | $205.00K 10-Q · filed 2019-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |